Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 383 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Melphalan October 1, 2020 Closing the gap: How new screening interventions could reduce inequalities in... July 5, 2022 Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates... October 18, 2023 Holiday Coping and Enjoying December 17, 2021 Load more HOT NEWS Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... Initial Results of the CanScreen5, an Authentic Data Repository for Cancer... ESMO Releases New Patient Guide in Hepatocellular Carcinoma ΠΩΣ ΠΡΟΚΑΛΕΙΤΑΙ
